(MENAFN- GlobeNewsWire - Nasdaq)
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- eyenovia, inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will present at the BTIG Ophthalmology Day taking place virtually on November 29, 2022. Presentation details are below:
BTIG Ophthalmology Day
| Date: || Tuesday, November 29, 2022 |
| || |
| Time: || 1:30 – 1:55 PM ET |
The Eyenovia management team will be participating in one-on-one meetings at the event. Investors interested in meeting with Eyenovia at either conference should contact their BTIG representative.
About Eyenovia, Inc.
Eyenovia, Inc. (Nasdaq: EYEN) is a pre-commercial ophthalmic technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.
The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.
Chief Financial Officer
Eyenovia Investor Contact:
LifeSci Advisors, LLC
Eyenovia Media Contact:
Vice President, Commercial Operations
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.